Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Update

Aura Biosciences, Inc. (NASDAQ:AURA) was the recipient of a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 1,120,000 shares, a decline of 13.2% from the February 13th total of 1,290,000 shares. Currently, 2.5% of the shares of the stock are sold short. Based on an average trading volume of 158,600 shares, the short-interest ratio is presently 7.1 days.

Insider Buying and Selling

In related news, insider Los Pinos Elisabet De sold 15,955 shares of Aura Biosciences stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total value of $122,374.85. Following the transaction, the insider now owns 304,692 shares of the company’s stock, valued at approximately $2,336,987.64. This trade represents a 4.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 23,045 shares of company stock valued at $177,242 over the last three months. Company insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Aura Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of AURA. BNP Paribas Financial Markets acquired a new stake in shares of Aura Biosciences during the 4th quarter valued at about $50,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Aura Biosciences during the 4th quarter valued at about $87,000. ProShare Advisors LLC acquired a new stake in shares of Aura Biosciences during the 4th quarter valued at about $127,000. Harvest Investment Services LLC acquired a new stake in shares of Aura Biosciences during the 4th quarter valued at about $133,000. Finally, AlphaQuest LLC acquired a new stake in shares of Aura Biosciences during the 4th quarter valued at about $136,000. Hedge funds and other institutional investors own 96.75% of the company’s stock.

Aura Biosciences Price Performance

NASDAQ:AURA opened at $7.49 on Thursday. Aura Biosciences has a fifty-two week low of $6.63 and a fifty-two week high of $12.38. The stock’s 50-day moving average is $7.67 and its two-hundred day moving average is $8.66. The stock has a market cap of $374.13 million, a PE ratio of -4.33 and a beta of 0.30.

Analyst Upgrades and Downgrades

Separately, Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a research note on Friday, January 31st. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $23.00.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.